The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis

BACKGROUND: The addition of human epidermal growth factor receptor 2 (Her2) therapies to neoadjuvant chemotherapy (NAC) during treatment of Her2-positive breast cancer has been proposed as an effective way to improve the prognosis. However, the treatment outcomes of adding trastuzumab, lapatinib, or...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Onco Targets Ther
Autores principales: Chen, Zhe-Ling, Shen, Yan-Wei, Li, Shu-Ting, Li, Chun-Li, Zhang, Ling-Xiao, Yang, Jiao, Lv, Meng, Lin, Ya-Yun, Wang, Xin, Yang, Jin
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4892834/
https://ncbi.nlm.nih.gov/pubmed/27313469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S106055
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares